Results 11 to 20 of about 5,337 (191)
Aducanumab: Appropriate Use Recommendations [PDF]
The Journal of Prevention of Alzheimer's Disease, 2021 Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based on the participant populations, conduct of the pivotal trials of aducanumab, updated ...
Cummings, J. +5 more
core +10 more sources
International Journal of Medical Science and Clinical Research Studies, 2022 Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD) but many uncertainties remain regarding both efficacy and safety. Of paramount concern are associated adverse effects including cerebral edema and hemorrhage which prompted a post-approval study.
Asia Filatov, MD +1 more
openaire +3 more sources
Cost Effectiveness and Resource Allocation, 2023 Background Alzheimer's Disease (AD), the most common type of dementia, is a chronic, progressive, and neurodegenerative brain discomfort that causes the be damage to brain cells.
Vahit Yigit +2 more
doaj +2 more sources
Drugs, 2021 Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid β. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease.
Sohita Dhillon (4873375)
openaire +3 more sources
Aducanumab: Appropriate Use Recommendations Update [PDF]
The Journal of Prevention of Alzheimer's Disease, 2022 Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab.
Cummings, Jeffrey +10 more
openaire +5 more sources
Making the Case for the Accelerated Withdrawal of Aducanumab [PDF]
Journal of Alzheimer's Disease, 2022 U.S. Food and Drug Administration–s (FDA) approval of aducanumab (Aduhelm® in the US) as a treatment for mild cognitive impairment of the Alzheimer type and Alzheimer–s disease has raised such major concerns about efficacy, safety, FDA processes, and regulatory capture that Biogen–s license to market this biologic should be immediately withdrawn ...
Peter J, Whitehouse, Vikas, Saini
openaire +3 more sources
Making the Case for Accelerated Withdrawal of Aducanumab [PDF]
Journal of Alzheimer's Disease, 2022 The controversial approval in June 2021 by the Food and Drug Administration (FDA) of aducanumab (marketed as Aduhelm), Biogen’s monoclonal antibody for patients with Alzheimer’s disease, raises significant concerns for the dementia field and drug approval process, considering its lack of adequate evidence for clinical efficacy, safety issues, and cost.
Whitehouse, Peter +16 more
openaire +6 more sources
Aducanumab for the treatment of Alzheimer's disease
Drugs of Today, 2022 Alzheimer's disease (AD) is the most frequent neurodegenerative condition, the most common cause of dementia, and a leading cause of disability and death globally. Mounting evidence supported accumulation of amyloid β (Aβ) as the primary cause of AD pathology and sprouted a number of candidate treatments engaging Aβ from its production to its clearance,
M. Tagliapietra, Tagliapietra, Matteo
openaire +4 more sources
Aducanumab for Alzheimer’s disease? [PDF]
BMJ, 2021 Patients and families need hope, not false ...
Walsh, Sebastian +3 more
openaire +2 more sources
Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know [PDF]
, 2021 In October 2019, the American pharmaceutical company Biogen stated intention to apply to the US Food and Drug Administration (FDA) for the candidate drug aducanumab to be licenced as a therapeutic agent for the treatment of Alzheimer's disease (AD).
Joel Petch +5 more
core +1 more source